These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 33353063)

  • 1. A Review of the Evidence for and against a Role for Mast Cells in Cutaneous Scarring and Fibrosis.
    Wilgus TA; Ud-Din S; Bayat A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33353063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mast Cells in Skin Scarring: A Review of Animal and Human Research.
    Ud-Din S; Wilgus TA; Bayat A
    Front Immunol; 2020; 11():552205. PubMed ID: 33117341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of basic fibroblast growth factor and its receptor by fibroblast, macrophages and mast cells in hypertrophic scar.
    Akimoto S; Ishikawa O; Iijima C; Miyachi Y
    Eur J Dermatol; 1999; 9(5):357-62. PubMed ID: 10417437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - Keloids and hypertrophic scars may be vascular disorders.
    Ogawa R; Akaishi S
    Med Hypotheses; 2016 Nov; 96():51-60. PubMed ID: 27959277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Inflammasomes in Keloids and Hypertrophic Scars-Lessons Learned from Chronic Diabetic Wounds and Skin Fibrosis.
    Huang C; Ogawa R
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and upcoming therapies to modulate skin scarring and fibrosis.
    Coentro JQ; Pugliese E; Hanley G; Raghunath M; Zeugolis DI
    Adv Drug Deliv Rev; 2019 Jun; 146():37-59. PubMed ID: 30172924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay Between Keratinocytes and Fibroblasts: A Systematic Review Providing a New Angle for Understanding Skin Fibrotic Disorders.
    Russo B; Brembilla NC; Chizzolini C
    Front Immunol; 2020; 11():648. PubMed ID: 32477322
    [No Abstract]   [Full Text] [Related]  

  • 8. Mast cells in pathological and surgical scars.
    Beer TW; Baldwin H; West L; Gallagher PJ; Wright DH
    Br J Ophthalmol; 1998 Jun; 82(6):691-4. PubMed ID: 9797674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune cells and associated molecular markers in dermal fibrosis with focus on raised cutaneous scars.
    Kidzeru EB; Lebeko M; Sharma JR; Nkengazong L; Adeola HA; Ndlovu H; P Khumalo N; Bayat A
    Exp Dermatol; 2023 May; 32(5):570-587. PubMed ID: 36562321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars.
    Bock O; Yu H; Zitron S; Bayat A; Ferguson MW; Mrowietz U
    Acta Derm Venereol; 2005; 85(3):216-20. PubMed ID: 16040405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smad interacting protein 1 as a regulator of skin fibrosis in pathological scars.
    Zhang ZF; Zhang YG; Hu DH; Shi JH; Liu JQ; Zhao ZT; Wang HT; Bai XZ; Cai WX; Zhu HY; Tang CW
    Burns; 2011 Jun; 37(4):665-72. PubMed ID: 21236582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of In Vitro Reconstructed Human Normotrophic, Hypertrophic, and Keloid Scar Models.
    Limandjaja GC; van den Broek LJ; Breetveld M; Waaijman T; Monstrey S; de Boer EM; Scheper RJ; Niessen FB; Gibbs S
    Tissue Eng Part C Methods; 2018 Apr; 24(4):242-253. PubMed ID: 29490604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cellular Response of Keloids and Hypertrophic Scars to Botulinum Toxin A: A Comprehensive Literature Review.
    Austin E; Koo E; Jagdeo J
    Dermatol Surg; 2018 Feb; 44(2):149-157. PubMed ID: 29401161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis.
    Ogawa R
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28287424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mast cell analyses in hypertrophic scars, hypertrophic scars treated with pressure and mature scars.
    Kischer CW; Bunce H; Shetlah MR
    J Invest Dermatol; 1978 Jun; 70(6):355-7. PubMed ID: 649983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extensive CD34-to-CD90 Fibroblast Transition Defines Regions of Cutaneous Reparative, Hypertrophic, and Keloidal Scarring.
    Ho JD; Chung HJ; Ms Barron A; Ho DA; Sahni D; Browning JL; Bhawan J
    Am J Dermatopathol; 2019 Jan; 41(1):16-28. PubMed ID: 30320623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Through gap junction communications, co-cultured mast cells and fibroblasts generate fibroblast activities allied with hypertrophic scarring.
    Foley TT; Ehrlich HP
    Plast Reconstr Surg; 2013 May; 131(5):1036-1044. PubMed ID: 23629085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets.
    Nguyen JK; Austin E; Huang A; Mamalis A; Jagdeo J
    Arch Dermatol Res; 2020 Mar; 312(2):81-92. PubMed ID: 31493000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic factors that shape cutaneous pathological scarring.
    Huang C; Ogawa R
    FASEB J; 2020 Oct; 34(10):13171-13184. PubMed ID: 32856341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The link between hypertension and pathological scarring: does hypertension cause or promote keloid and hypertrophic scar pathogenesis?
    Huang C; Ogawa R
    Wound Repair Regen; 2014; 22(4):462-6. PubMed ID: 24899409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.